Compare Bristol-Myers Squibb Co (BMY) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Open Text Corporation — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Open Text Corporation trades at $22.58 (market cap $5.40B). The key difference: Bristol-Myers Squibb Co is far larger — about 21.5× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.9%). Which is the better fit depends on your goals.
| BMY | OTEX | |
|---|---|---|
Market Cap | $116.30B | $5.40B |
Sector | Health | Technology |
52-Week High | $62.37 | $39.69 |
52-Week Low | $42.60 | $20.01 |
Enterprise Value | $152.24B | $10.56B |
Dividend Yield | 4.42% | 4.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
OpenText (OTEX) trades at $23.57, up 2.43% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 73.06% gross margin and has beaten earnings estimates for the last three quarters. Recent strategic moves include a $105 million investment in European AI and cloud expansion and the divestiture of the non-core Vertica business.
The outlook is positive, supported by a consensus analyst price target of $29.75, implying significant upside. Key opportunities include margin expansion and AI-driven growth, while risks involve integration of strategic shifts and competitive pressures in the enterprise software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
